AstraZeneca signs USD 40 million AI deal as AstraZeneca stock trades EUR 149.78
Published on 10/21/2026 at 09:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDrug discovery and reporting dates
- AstraZeneca entered an insitro collaboration with a USD 40 million upfront payment on October 15, 2026.
- Second-quarter 2026 revenue reached USD 15.38 billion, up 6.40 percent from the prior year.
- AstraZeneca stock was trading at EUR 149.78 at 9:48 a.m. CEST at Lang & Schwarz on October 21, 2026.
AstraZeneca (ISIN GB0009895292) entered a strategic collaboration with insitro on October 15, 2026, including a USD 40 million upfront payment, according to AstraZeneca. At Lang & Schwarz, the stock was trading at EUR 149.78 at 9:48 a.m. CEST on October 21, 2026.
AI deal targets two diseases
The agreement covers metabolic dysfunction-associated steatohepatitis and cardiomyopathies. insitro will use its Virtual Human platform to identify disease biology and advance AstraZeneca-nominated targets from discovery toward development candidates.
The financial structure puts the immediate commitment at USD 40 million. insitro may also receive up to USD 1.46 billion in development and commercial milestones, plus potential single-digit royalties on global sales, while AstraZeneca holds exclusive worldwide rights to selected programs.
Three dated catalysts
On July 27, 2026, AstraZeneca reported second-quarter revenue of USD 15.38 billion, up 6.40 percent year over year, while adjusted earnings per share reached USD 2.63 against a USD 2.50 consensus estimate, according to MarketBeat. On October 15, the insitro agreement added the USD 40 million upfront payment. On October 21, AstraZeneca said it would present more than 100 abstracts at ESMO 2026, including data from four pivotal phase III trials, as PharmaBiz reported.
What dates matter next?
AstraZeneca's investor calendar lists an ESMO management event for October 26, 2026, followed by the company's 9M and third-quarter 2026 results on October 30, 2026, on the AstraZeneca investor-relations page. The results will provide the next reported test of revenue growth, earnings and the full-year outlook.
Stock stays in pre-market trading
The October 21 quote places AstraZeneca in the pre-market phase for German investors. The company enters the next reporting window with a second-quarter revenue comparison, a large discovery partnership and a dense oncology data schedule.
AstraZeneca was trading at EUR 149.78 at Lang & Schwarz on October 21, 2026 at 9:48 a.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.
AstraZeneca stock facts
- Company: AstraZeneca plc
- ISIN: GB0009895292
- Ticker: AZN
- Primary exchange: London Stock Exchange
- Price Lang & Schwarz (as of October 21, 2026, 9:48 a.m. CEST): EUR 149.78
- Market capitalization: USD 261.8 billion (as of October 20, 2026)
- Sector / Industry: Biopharmaceuticals
Market context: Market report FTSE 100.
